A pediatric study from London with 19 patients demonstrates the utility of taurolidine line locks (JPGN 2012; 55: 403-7).
Taurolidine has broad antimicrobial activity against Gram-positive and Gram-negative bacteria in addition to antifungal properties. Also, taurolidine prevents biofilm formation which can help minimize colonization of catheters. It acts by binding to the cell walls of organisms; this results in the prevention of bacterial adhesion to biological surfaces. TauroLock™ | TauroLock™
15 of the 19 patients had a history of recurrent central catheter infections and 4 were started on the line locks empirically. At the completion of the parenteral nutrition, 0.7 to 1 mL of the taurolidine solution was instilled and left for at least 12 hours.
Taurolidine-treated patients had 1.1 episodes per 100 catheter days of CVL infections; this compared with a rate of 8.6 episodes per 1000 catheter days for heparin control. Furthermore, 74% (14) had no infections for up to 33 months after changing to taurolidine. No reports of mulitresistant organisms or adverse effects were reported. Taurolidine is nontoxic for humans and rapidly metabolized to taurine, carbon dioxide, and water.
To my knowledge, taurolidine is not available in the U.S. Nevertheless, the data on line locks indicate that antimicrobial line locks are associated with reductions in catheter infections.
Related blog entries:
- IFfy outcome | gutsandgrowth
- More on ethanol locks | gutsandgrowth
- Four advances for intestinal failure | gutsandgrowth: